Duke Energy Foundation, City of New Port Richey Team Up for Summer Swim Safety
'Safety is central to how we operate at Duke Energy. Providing water safety education through swim lessons is a fun but important way to keep children in our community safe this summer,' said Melissa Seixas, Duke Energy Florida state president. 'We thank the City of New Port Richey for providing programming to families throughout the year and are happy to make these programs available to more children this summer.'
The City of New Port Richey is offering summer day camp to residents June 2-Aug. 8 this summer. Registration is available by calling the Recreation and Aquatic Center at 727.841.4560 or visiting www.citynpr.org. Limited spots are still available.
'We're incredibly grateful to Duke Energy Foundation for supporting our efforts to keep kids safe and active all summer long,' said Kevin Trapp, assistant parks and recreation director. 'This funding helps remove barriers for families and ensures more children can enjoy swim lessons and camp experiences that build confidence and lifelong safety skills.'
Below are the top water safety tips from the American Red Cross, as an important reminder to all of us, on how to keep yourself, your family and friends safe in and around the water every day.
For more information on water safety, please visit American Red Cross' water safety resources here.
Duke Energy Foundation
Duke Energy Foundation provides more than $30 million annually in philanthropic support to meet the needs of communities where Duke Energy customers live and work. The Foundation is funded by Duke Energy shareholders.
Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of America's largest energy holding companies. The company's electric utilities serve 8.6 million customers in North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky, and collectively own 55,100 megawatts of energy capacity. Its natural gas utilities serve 1.7 million customers in North Carolina, South Carolina, Tennessee, Ohio and Kentucky.
About Duke Energy FloridaDuke Energy Florida, a subsidiary of Duke Energy, owns 12,500 megawatts of energy capacity, supplying electricity to 2 million residential, commercial and industrial customers across a 13,000-square-mile service area in Florida.
About City of New Port Richey:
With a strong local government, an attractive historical downtown, and a unique riverfront landscape, New Port Richey is one of Florida's best walkable, waterfront, historic hometowns. For more information, visit www.cityofnewportrichey.org.
Media contact: Laitin SterlingMedia line: 800.559.3853
View original content here.
Visit 3BL Media to see more multimedia and stories from Duke Energy Corporation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Lilly's Mounjaro Exhibits Heart Benefits In Type 2 Diabetes Landmark Trial
Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,000 adults with cardiovascular disease and type 2 diabetes. Mounjaro reported higher decreases in body weight (−11.43 kg vs. −4.65 kg), A1C (1.73% vs. 0.90%), and a slowed decline in kidney function by 3.54 mL/min/1.73 m² at 36 months, along with a drop in all-cause mortality by 16%. Mounjaro, a GIP/GLP-1 dual receptor agonist, performed better than Trulicity, a GLP-1 agonist, in several important endpoints in the longest and most extensive tirzepatide trial to date. The 4.5-year research, which covered 30 countries, reaffirmed Mounjaro's tolerability and safety. According to a predetermined indirect analysis, Mounjaro decreased all-cause mortality by 39% and MACE-3 by 28% when compared to a placebo. Eli Lilly and Company (NYSE:LLY) will discuss all of the findings at the 2025 EASD meeting and aims to submit regulatory applications by year's end. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 hours ago
- Yahoo
Aflac Incorporated Announces Increase in Shares Authorized for Repurchase
COLUMBUS, Ga., Aug. 12, 2025 /PRNewswire/ -- Aflac Incorporated (NYSE: AFL) today announced that its Board of Directors has authorized the purchase of up to 100 million shares of its common stock. This authorization is in addition to the 30.9 million shares as of June 30, 2025, that remained under the November 8, 2022 authorization, bringing the total number of shares available for purchase to approximately 130.9 million. The company anticipates that the repurchase of shares will be conducted from time to time in open market or negotiated transactions, depending on market conditions. ABOUT AFLAC INCORPORATED Aflac Incorporated (NYSE: AFL), a Fortune 500 company, has helped provide financial protection and peace of mind for nearly seven decades to millions of policyholders and customers through its subsidiaries in the U.S. and Japan. In the U.S., Aflac is the No. 1 provider of supplemental health insurance products.1 In Japan, Aflac Life Insurance Japan is the leading provider of cancer and medical insurance in terms of policies in force. The company takes pride in being there for its policyholders when they need us most, as well as being included in the World's Most Ethical Companies by Ethisphere for 19 consecutive years (2025) and Fortune's World's Most Admired Companies for 24 years (2025). In addition, the company became a signatory of the Principles for Responsible Investment (PRI) in 2021 and has been included in the Dow Jones Sustainability North America Index (2024) for 11 years. To find out how to get help with expenses health insurance doesn't cover, get to know us at or Investors may learn more about Aflac Incorporated and its commitment to corporate social responsibility and sustainability at under "Sustainability." 1 LIMRA 2024 U.S. Supplemental Health Insurance Total Market Report FORWARD-LOOKING INFORMATION The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" to encourage companies to provide prospective information, so long as those informational statements are identified as forward-looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those included in the forward-looking statements. Aflac Incorporated (the Parent Company) and its subsidiaries (collectively with the Parent Company, the Company) desire to take advantage of these provisions. This document contains cautionary statements identifying important factors that could cause actual results to differ materially from those projected herein, and in any other statements made by Company officials in communications with the financial community and contained in documents filed with the Securities and Exchange Commission (SEC). Forward-looking statements are not based on historical information and relate to future operations, strategies, financial results or other developments. Furthermore, forward-looking information is subject to numerous assumptions, risks and uncertainties. In particular, statements containing words such as "expect," "anticipate," "believe," "goal," "objective," "may," "should," "estimate," "intends," "projects," "will," "assumes," "potential," "target," "outlook" or similar words as well as specific projections of future results, generally qualify as forward-looking. The Company undertakes no obligation to update such forward-looking statements. The Company cautions readers that the following factors, in addition to other factors mentioned from time to time, could cause actual results to differ materially from those contemplated by the forward-looking statements: difficult conditions in global capital markets and the economy, including inflation defaults and credit downgrades of investments global fluctuations in interest rates and exposure to significant interest rate risk concentration of business in Japan limited availability of acceptable yen-denominated investments foreign currency fluctuations in the yen/dollar exchange rate differing interpretations applied to investment valuations significant valuation judgments in determination of expected credit losses recorded on the Company's investments decreases in the Company's financial strength or debt ratings decline in creditworthiness of other financial institutions the Company's ability to attract and retain qualified sales associates, brokers, employees, and distribution partners deviations in actual experience from pricing and reserving assumptions ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality, integrity or privacy of sensitive data residing on such systems, and uncertainty regarding the impact of the incident involving unauthorized access to the Company's network in June 2025 subsidiaries' ability to pay dividends to the Parent Company inherent limitations to risk management policies and procedures operational risks of third-party vendors tax rates applicable to the Company may change failure to comply with restrictions on policyholder privacy and information security extensive regulation and changes in law or regulation by governmental authorities competitive environment and ability to anticipate and respond to market trends catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events ability to protect the Aflac brand and the Company's reputation ability to effectively manage key executive succession changes in accounting standards level and outcome of litigation or regulatory inquiries allegations or determinations of worker misclassification in the United States Analyst and investor contact - David A. Young, 706.596.3264 or 800.235.2667 or dyoung@ Media contact – Ines Gutzmer, 762.207.7601 or igutzmer@ View original content to download multimedia: SOURCE Aflac Incorporated
Yahoo
14 hours ago
- Yahoo
Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the 'Company'), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and second quarter 2025 financial results. 'In the past quarter, our efforts were centered on driving enrollment for the pivotal Phase 3 trial in early AD, which now includes 76 secured clinical sites across the U.S. and over 400 patients screened to date,' said Maria Maccecchini, Ph.D., President and CEO of Annovis. 'At the same time, we reached other notable milestones, including presenting our latest scientific findings at AAIC 2025 with the largest attendance ever from Annovis team and strengthening our global intellectual property protection by completing the transfer of all patent families to crystal buntanetap. As we move forward, our focus stays firmly on completing enrollment as planned to produce strong and trustworthy results, while also advancing our Parkinson's program, with more updates coming as we progress.' Clinical highlights Annovis' pivotal Phase 3 study in early AD (NCT06709014) is advancing rapidly, with 76 U.S. sites secured and 46 currently enrolling patients. The remaining sites are expected to begin enrollment shortly. The pivotal Phase 3 trial has attracted strong participation, with 38 patients already receiving buntanetap or placebo and nearly 200 more in screening – a number that continues to grow each day – with screen failure rate being as expected at 50%. Business highlights In April, Annovis welcomed Hui Liu as Director of Biostatistics, who is responsible for maintaining statistical integrity of the data generated by the Company's clinical trials. In June, Annovis hosted a webcast to provide updates on its Phase 3 trial, engaging directly with the audience through a live Q&A session. The recording is available in the Video Library on the Company's website. In July, senior members of Annovis attended AAIC 2025 in Toronto, presenting four scientific posters highlighting advancements in the Alzheimer's Phase 3 study and the pharmacokinetic profile of its lead drug candidate, buntanetap. All posters are available in the Media Library on the Company's website. In August, Annovis announced the successful transfer of all patent families to crystal buntanetap, achieving comprehensive global IP coverage for both the original and new forms of the Company's drug candidate. Financial results Annovis' cash and cash equivalents totaled $17.1 million as of June 30, 2025, compared to $10.6 million as of December 31, 2024. The Company had 19.5 million shares of common stock outstanding as of June 30, 2025. Research and development expenses for the three months ending June 30, 2025, were $5.2 million compared to $5.8 million for the three months ending June 30, 2024. General and administrative expenses for the three months ending June 30, 2025, were $1.1 million compared to $2.0 million for the three months ending June 30, 2024. Annovis reported a $0.32 basic and diluted net loss per common share for the three months ending June 30, 2025, compared to a $0.44 basic and diluted net loss per common share for the three months ending June 30, 2024. About Annovis Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn, YouTube, and X. Investor AlertsInterested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for email alerts at Forward-Looking StatementsThis press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. Actual results may differ due to various risks and uncertainties, including those outlined in the Company's SEC filings under 'Risk Factors' in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law. Contact Information:Annovis Bio Inc.101 Lindenwood DriveSuite 225Malvern, PA Investor Contact:Alexander Morin, Strategic CommunicationsAnnovis Bioir@ (Tables to follow) ANNOVIS BIO, INC. Balance Sheets (Unaudited) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 17,130,286 $ 10,551,916 Prepaid expenses and other current assets 4,324,285 3,373,717 Total assets $ 21,454,571 $ 13,925,633 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 974,311 $ 2,305,974 Accrued expenses 1,830,813 1,575,013 Total current liabilities 2,805,124 3,880,987 Non-current liabilities: Warrant liability 319,000 737,000 Total liabilities 3,124,124 4,617,987 Commitments and contingencies Stockholders' equity: Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding — — Common stock - $0.0001 par value, 70,000,000 shares authorized, 19,486,231 and 14,141,521 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 1,948 1,414 Additional paid-in capital 164,935,088 144,155,694 Accumulated deficit (146,606,589 ) (134,849,462 ) Total stockholders' equity 18,330,447 9,307,646 Total liabilities and stockholders' equity $ 21,454,571 $ 13,925,633 ANNOVIS BIO, INC. Statements of Operations (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 5,161,921 $ 5,785,217 $ 10,173,438 $ 12,307,308 General and administrative 1,109,532 1,977,421 2,380,696 3,265,137 Total operating expenses 6,271,453 7,762,638 12,554,134 15,572,445 Operating loss (6,271,453 ) (7,762,638 ) (12,554,134 ) (15,572,445 ) Other income (expense): Interest income 191,395 25,978 379,007 70,146 Other financing costs — (1,346,060 ) — (1,346,060 ) Change in fair value of warrants (140,000 ) 4,062,308 418,000 10,761,000 Total other income, net 51,395 2,742,226 797,007 9,485,086 Net loss $ (6,220,058 ) $ (5,020,412 ) $ (11,757,127 ) $ (6,087,359 ) Net loss per share Basic $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (0.56 ) Diluted $ (0.32 ) $ (0.44 ) $ (0.64 ) $ (1.52 ) Weighted-average number of common shares used in computing net loss per share Basic 19,486,231 11,307,759 18,464,877 10,966,412 Diluted 19,486,231 11,307,759 18,464,877 11,066,265
